• Metastatic Melanoma - B-Raf Inhibition and Beyond
  • CME

  • Metastatic Melanoma - B-Raf Inhibition and Beyond

  • Author(s)/Faculty: David B. Solit, MD; Sanjiv S. Agarwala, MD; Keith Flaherty, MD
    Source: HemOnc Today
    Type: Multimedia Articles/Items: 3
    Release Date: 7/27/2011 Expiration Date: 7/26/2012
    Credit Type: CME Number of Credit(s): 1
    Cost: Free Provider: Vindico Medical Education
  • Melanoma, the fifth most common cancer and the deadliest form of skin cancer, is diagnosed in 68,130 patients and claims 8,700 individuals per year. Although it can be curable if caught early, treatment options are limited for patients with advanced disease, and prognosis is poor. Earlier detection, appropriate staging, individualized treatment, and the use of new therapies, when they become available, are the most promising options for improving patient prognosis and relieving the growing public health burden of melanoma. In this activity, leading clinicians will offer practical recommendations based on the state of the science and recent clinical trials that can be employed immediately to improve outcomes for patients with melanoma.

Sponsorship Statement:
This continuing education activity is jointly sponsored by and

Support Statement:
The content contained in this activity was developed from the live activity that was supported, in part, by educational grants from
and .

Target Audience:
This program is designed for oncologists and dermatologists.

Learning Objectives:
At the conclusion of this activity participants should be able to:

  • Review potential benefits and adverse effects of emerging therapeutic agents for the treatment of primary cutaneous malignancies and metastatic disease.
  • Analyze late-breaking research findings presented at recent major scientific meetings such as ASCO and ESMO and assess their clinical applicability.
  • Explore outcomes from investigative clinical trials that involve the use of adjuvant chemotherapy and novel biologics for the treatment of advanced melanoma.

Faculty:
Sanjiv S. Agarwala, MD
Editorial Board Member
HemOnc Today
Chief, Medical Oncology and Hematology
St. Luke’s Cancer Center
Bethlehem, PA
Professor of Medicine
Temple University
Philadelphia, Pennsylvania
Talk Title: Recent ASCO Data on Vemurafenib

Keith T. Flaherty, MD
Associate Professor
Harvard Medical School
Director of Developmental Therapeutics
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Talk Titles: Vertical Blockade: Is MEK Important? and How are the B-Raf-Targeted Therapies Going to Change the Therapeutic Landscape?

David B. Solit, MD
Elizabeth and Felix Rohatyn Chair
Memorial Sloan-Kettering
Cancer Center
New York, New York
Talk Title: Highly Selective Inhibitors of the B-Raf Pathway: Current Data

External Reviewer:
William Lloyd, MD

Accreditation:
This educational activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of HemOnc Today® and Vindico Medical Education. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Vindico Medical Education designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, July 27, 2011 to July 26, 2012.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch and listen to the presentations, complete the posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate.

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):
Sanjiv S. Agarwala, MD
Speakers’ Bureau: Novartis, Merck
Keith T. Flaherty, MD
Consulting Fees: GlaxoSmithKline, Genentech, Roche
David B. Solit, MD
Consulting Fees: AstraZeneca, GlaxoSmithKline, Roche

External Reviewer reports the following relationship(s):
William Lloyd, MD (employee of Vindico Medical Education)
No relevant financials relationships to disclose

HemOnc Today® and Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA. Copyright © 2011 SLACK Incorporated®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and HemOnc Today® continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and HemOnc Today®. Neither Vindico Medical Education, HemOnc Today®, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.